您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Fleroxacin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Fleroxacin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Fleroxacin图片
CAS NO:79660-72-3
包装与价格:
包装价格(元)
500mg电议
1 g电议
5 g电议
10 g电议

产品介绍
Fleroxacin (RO 23-6240) 是一种广谱抗菌氟喹诺酮类药物。
Cas No.79660-72-3
别名氟罗沙星; RO 23-6240; AM-833
化学名6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Canonical SMILESCN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F
分子式C17H18F3N3O3
分子量369.34
溶解度DMF: 0.1 mg/ml,DMSO: 15 mg/ml,PBS (pH 7.2): 10 mg/ml
储存条件4°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Fleroxacin (RO 23-6240) is a broad-spectrum antimicrobial fluoroquinolone.

Fleroxacin (Ro 23-6240) is a new trifluorinated quinolone exhibiting high activity against a broad spectrum of gram-negative and gram-positive bacteria. Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg)[1]. Fleroxacin (Ro 23-6240) is effective against Haemophilus ducreyi in vitro. Fleroxacin (Ro 23-6240), 200 or 400 mg as a single oral dose, is efficacious therapy for microbiologically proven chancroid in patients who do not have concurrent HIV-1 infection. Among HIV-1-infected men, a single dose of 200 or 400 mg of fleroxacin is inadequate therapy for chancroid[2][3].

References:
[1]. Weidekamm, E., et al., Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob Agents Chemother, 1987. 31(12): p. 1909-14.
[2]. MacDonald, K.S., et al., Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. Antimicrob Agents Chemother, 1989. 33(5): p. 612-4.
[3]. Rubinstein, E., History of quinolones and their side effects. Chemotherapy, 2001. 47 Suppl 3: p. 3-8; discussion 44-8.